Seeking Alpha

Idenix Pharmaceuticals (IDIX) moves up 5.2% premarket after announcing that the FDA released a...

Idenix Pharmaceuticals (IDIX) moves up 5.2% premarket after announcing that the FDA released a partial clinical hold on the firm's study on HCV nucleotide inhibitor IDX184. The firm says the decision will allow it to expand a phase IIb program on the drug.
Comments (1)
  • EXPstocktrader
    , contributor
    Comments (393) | Send Message
     
    BofA / Merrill Lynch upgrades $IDIX near the close on Friday, Feb 3rd to $18...Holding $ACHN too for $20 buy out...Patience.
    3 Feb 2012, 04:26 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs